Stemline Therapeutics (STML) Misses Q2 EPS by 17c
Tweet
Share
E-mailGet Alerts STML Hot Sheet
Join SI Premium – FREE
Stemline Therapeutics (NASDAQ: STML) reported Q2 EPS of ($0.58), $0.17 worse than the analyst estimate of ($0.41).
For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Is Treasury selloff a major issue for stock market bulls?
- Securitize Corp (SECZ) PT Lowered to $10 at Benchmark as Stock Plummets Post Q2 Earnings
- The LGL Group (LGL) Misses Q2 EPS by 8c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
